Trial intelligence / Profile preview

Half-side randomized comparison of MAL daylight PDT with or without calcitriol pretreatment for actinic keratosis of the upper extremities

2018-000545-39Phase 3Completed

Sponsor
ASL 1 Avezzano-Sulmona-L'Aquila
Start
May 2021
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3, randomised, open-label trial in actinic keratosis (AK) comparing Calcitriol pretreatment plus MAL daylight PDT with MAL daylight PDT alone (2 arms). Primary endpoint: Complete lesion response rate of actinic keratoses. Started May 2021; status: completed.

02

Drugs

methyl aminolevulinatecalcitriol
03

Conditions

actinic keratosis (AK)

Beyond the preview

Go deeper on 2018-000545-39.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2018-000545-39.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call